Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 11/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 10/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 8/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128143 | 0.76 | ALDH1A1 (0.47) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL1526202 | 0.74 | — | — | |
| SCHEMBL6826193 | 0.72 | NAMPT (0.39) | LMNA | |
| SCHEMBL2652708 | 0.71 | ALDH1A1 (0.55) | HPGDSGABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL29550139 | 0.71 | ALDH1A1 (0.55) | HPGDSGABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL4076647 | 0.71 | PAX8 (0.39) | LMNAGPR119 | |
| SCHEMBL30489013 | 0.70 | P2RX7 (0.47) | HPGDSGABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL946380 | 0.70 | P2RX7 (0.50) | HPGDSGABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL32315381 | 0.70 | P2RX7 (0.50) | HPGDSGABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL27694230 | 0.70 | P2RX7 (0.47) | HPGDSGABRG2GABRB3GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017278-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD KK (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8791125-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | SAGARA TAKESHI | 2011-08-04 | — | — | US | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| CN-101432284-A | Dihydropyrazolopyrimidinone derivative | BANYU PHARMA CO LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | HPGDS 2793/4885GABRG2 4092/4885GABRB3 3926/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | HPGDS 2793/4885GABRG2 4092/4885GABRB3 3926/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | HPGDS 2793/4885GABRG2 4092/4885GABRB3 3926/4885 |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | HPGDS 2793/4885GABRG2 4092/4885GABRB3 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.